Advertisement

Cancer Immunology, Immunotherapy

, Volume 56, Issue 12, pp 1955–1965 | Cite as

Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression

  • Priyadarshini L. Ganesan
  • Stephen I. Alexander
  • Debbie Watson
  • Grant J. Logan
  • Geoff Y. Zhang
  • Ian E. Alexander
Original Article

Abstract

Successful immunotherapy of solid tumors has proven difficult to achieve. The aim of the current study was to further investigate the effects of peripheral CD80-mediated co-stimulation on the efficacy of polyclonal anti-tumor effector CTL in an adoptive transfer model. Splenocytes obtained from wild-type mice immunized with CD80-transduced EL4 tumor cells were expanded in vitro in the presence of either IL-12 or IL-15 and irradiated CD80-transduced EL4 tumor cells. Polyclonal CD8 T cells were the major subset in the effector population. Primed effector cells were adoptively transferred into immuno-deficient Rag-1-deficient mice which were then challenged with syngeneic vector-control or CD80-transduced EL4 tumor cells. Expression of CD80 enhanced the elimination of EL4 tumors and mouse survival. Both IL-12 and IL-15 cultured cells had enhanced cytotoxicity. Importantly, anti-tumor memory was maintained without tumor evasion following re-challenge with either CD80-transduced and vector-control EL4 cells. We also show, using antibody-mediated depletion, that endogenous NK cells present in Rag-1-deficent mice exert anti-EL4 tumor activity that is enhanced by CD80 expression. Collectively these data show that peripheral co-stimulation by tumor expression of CD80 results in enhanced anti-tumor efficacy of NK and polyclonal effector T cells, and suggest that TCR repertoire diversity helps protect against tumor escape and provides memory with resultant robust immunity to subsequent tumor challenge irrespective of CD80 status.

Keywords

Effector CTL Tumor-associated CD80 Cytokines NK cells 

Notes

Acknowledgments

We thank Christine Smyth for assistance with flow cytometry and Margot Latham for preparing figures and manuscript collation.

References

  1. 1.
    Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL (1992) Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 149:1115PubMedGoogle Scholar
  2. 2.
    Bai XF, Bender J, Liu J, Zhang H, Wang Y, Li O, Du P, Zheng P, Liu Y (2001) Local costimulation reinvigorates tumor-specific cytolytic t lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 167:3936PubMedGoogle Scholar
  3. 3.
    Bai XF, Liu J, Li O, Zheng P,Liu Y (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111:1487PubMedCrossRefGoogle Scholar
  4. 4.
    Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687PubMedCrossRefGoogle Scholar
  5. 5.
    Bertolino P, Trescol-Biemont MC,Rabourdin-Combe C (1998) Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 28:221PubMedCrossRefGoogle Scholar
  6. 6.
    Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM (2002) Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 169:4079PubMedGoogle Scholar
  7. 7.
    Cerwenka A, Lanier LL (2001) Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 181:158PubMedCrossRefGoogle Scholar
  8. 8.
    Chambers BJ, Salcedo M, Ljunggren HG (1996) Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5:311PubMedCrossRefGoogle Scholar
  9. 9.
    Chambers CA, Allison JP (1997) Co-stimulation in T cell responses. Curr Opin Immunol 9:396PubMedCrossRefGoogle Scholar
  10. 10.
    Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336PubMedCrossRefGoogle Scholar
  11. 11.
    Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093PubMedCrossRefGoogle Scholar
  12. 12.
    Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523PubMedCrossRefGoogle Scholar
  13. 13.
    Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609PubMedCrossRefGoogle Scholar
  14. 14.
    Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141PubMedCrossRefGoogle Scholar
  15. 15.
    Demirci G, Li XC (2004) IL-2 and IL-15 exhibit opposing effects on Fas mediated apoptosis. Cell Mol Immunol 1:123PubMedGoogle Scholar
  16. 16.
    Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165PubMedCrossRefGoogle Scholar
  17. 17.
    Dorshkind K, Pollack SB, Bosma MJ, Phillips RA (1985) Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 134:3798PubMedGoogle Scholar
  18. 18.
    Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515PubMedCrossRefGoogle Scholar
  19. 19.
    Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47PubMedCrossRefGoogle Scholar
  20. 20.
    Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552PubMedGoogle Scholar
  21. 21.
    Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ (2002) A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 168:4472PubMedGoogle Scholar
  22. 22.
    Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225PubMedCrossRefGoogle Scholar
  23. 23.
    Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233PubMedCrossRefGoogle Scholar
  24. 24.
    Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L (1994) Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421PubMedGoogle Scholar
  25. 25.
    Liu Y, Janeway CA Jr (1992) Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 89:3845PubMedCrossRefGoogle Scholar
  26. 26.
    Logan GJ, Spinoulas A, Alexander SI, Smythe JA, Alexander IE (2004) CD4 expression on EL4 cells as an epiphenomenon of retroviral transduction and selection. Immunol Cell Biol 82:132PubMedCrossRefGoogle Scholar
  27. 27.
    Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869PubMedCrossRefGoogle Scholar
  28. 28.
    Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, Altman JD, Katsikis PD (2003) IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101:1024PubMedCrossRefGoogle Scholar
  29. 29.
    Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. (2005) Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6:280PubMedCrossRefGoogle Scholar
  30. 30.
    Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615PubMedCrossRefGoogle Scholar
  31. 31.
    Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, Jabri B (2001) NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 167:5527PubMedGoogle Scholar
  32. 32.
    Schwartz RH (1996) Models of T cell anergy: is there a common molecular mechanism? J Exp Med 184:1PubMedCrossRefGoogle Scholar
  33. 33.
    Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116PubMedCrossRefGoogle Scholar
  34. 34.
    Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214PubMedCrossRefGoogle Scholar
  35. 35.
    Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753PubMedCrossRefGoogle Scholar
  36. 36.
    Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368PubMedCrossRefGoogle Scholar
  37. 37.
    Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A (2004) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 112:258PubMedCrossRefGoogle Scholar
  38. 38.
    Walker LS, Chodos A, Eggena M, Dooms H,Abbas AK (2003) Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 198:249PubMedCrossRefGoogle Scholar
  39. 39.
    Watson D, Zhang GY, Sartor M, Alexander SI (2004) “Pruning” of alloreactive CD4+ T cells using 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester prolongs skin allograft survival. J Immunol 173:6574PubMedGoogle Scholar
  40. 40.
    Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415PubMedCrossRefGoogle Scholar
  41. 41.
    Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM (1995) B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol 165:217PubMedCrossRefGoogle Scholar
  42. 42.
    Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL (2004) Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 173:3716PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Priyadarshini L. Ganesan
    • 1
  • Stephen I. Alexander
    • 2
  • Debbie Watson
    • 2
  • Grant J. Logan
    • 1
  • Geoff Y. Zhang
    • 2
  • Ian E. Alexander
    • 1
    • 3
    • 4
  1. 1.Gene Therapy Research UnitThe Children’s Hospital at Westmead and Children’s Medical Research InstituteWestmeadAustralia
  2. 2.The Centre for Kidney Research, The Children’s Hospital at WestmeadWestmeadAustralia
  3. 3.The University of Sydney Discipline of Paediatrics and Child HealthWestmeadAustralia
  4. 4.Gene Therapy Research Unit, The Children’s Hospital at WestmeadWestmeadAustralia

Personalised recommendations